8-​O-​Acetylharpagide

Synonyms: 8-O-乙酰哈巴苷
8-O-Acetylharpagide 是一种口服有效的环烯醚萜苷类化合物,低剂量下具有抗衰老活性,高剂量下具有抗癌活性,可诱导癌细胞发生晚期凋亡 (apoptosis) 和坏死样死亡,并下调 Akt、p-Akt、Bcl-2 等抗凋亡蛋白,在大鼠体内主要通过去甲基化、水解和葡萄糖醛酸化进行代谢,其活性代谢物可下调 AKT/NF-κB/MMP9 信号轴,并通过激动血管 α-肾上腺素受体 (α-adrenoceptor) 发挥血管收缩作用。
产品编号: MS-U77571 纯度: 99.75% CAS No.: 6926-14-3 分子式: C17H26O11 分子量: 406.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
20mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

8-O-Acetylharpagide 是一种口服有效的环烯醚萜苷类化合物,低剂量下具有抗衰老活性,高剂量下具有抗癌活性,可诱导癌细胞发生晚期凋亡 (apoptosis) 和坏死样死亡,并下调 Akt、p-Akt、Bcl-2 等抗凋亡蛋白,在大鼠体内主要通过去甲基化、水解和葡萄糖醛酸化进行代谢,其活性代谢物可下调 AKT/NF-κB/MMP9 信号轴,并通过激动血管 α-肾上腺素受体 (α-adrenoceptor) 发挥血管收缩作用。

生物实验数据

生物活性 8-O-Acetylharpagide is an orally active iridoid glycoside compound that exhibits anti-aging activity at low doses and anticancer activity at high doses, induces late apoptosis and necrotic-like death in cancer cells while downregulating anti-apoptotic proteins such as Akt, p-Akt, and Bcl-2, is metabolized in rats primarily via demethylation, hydrolysis, and glucuronidation with its active metabolites downregulating the AKT/NF-κB/MMP9 signaling axis, and exerts vasoconstrictive effects through agonism of vascular α-adrenoceptors.
体外研究
(In Vitro)

8-O-acetylharpagide (0.5-10 μM; 48 h) 可在体外以剂量依赖的方式抑制衰老的人真皮成纤维细胞中衰老相关 β-半乳糖苷酶的活性。
8-O-acetylharpagide (0.5-10 μM; 48 h) 可剂量依赖性地抑制衰老人类真皮成纤维细胞中的 p53 表达。
8-O-acetylharpagide (1-10 μM) 抑制老年人类真皮成纤维细胞中升高的细胞内活性氧水平。
8-O-acetylharpagide (2.5 mg/mL; 0-24 h) 在体外大鼠肠道菌群培养体系中会发生代谢转化,通过水解、还原和葡糖醛酸化等途径生成 2 种代谢产物。
8-O-acetylharpagide (0.01-1 mM; 24 h) 对人下咽癌 FaDu 细胞表现出比对人正常 PDL 细胞更强的选择性细胞毒性,处理 24 h 后其对 FaDu 细胞的 IC50 为 0.88 mM,对 PDL 细胞的 IC50 为 1.65 mM。
8-O-acetylharpagide (1 mM; 24 h) 可在人下咽癌 FaDu 细胞中诱导显著的细胞变圆,但在正常人 PDL 细胞中无此作用。
8-O-acetylharpagide (1 mM; 6 days) 可完全抑制人下咽癌 FaDu 细胞的增殖。
8-O-acetylharpagide (0.5-1 mM; 24 h) 可在人下咽癌 FaDu 细胞中诱导剂量依赖性 G2/M 期阻滞,并调控细胞周期相关蛋白的表达,但对人正常 PDL 细胞的细胞周期分布无影响。
8-O-acetylharpagide (1 mM; 24 h) 可诱导人下咽癌 FaDu 细胞发生显著的坏死样细胞死亡和晚期凋亡,并下调抗凋亡蛋白,但对正常人 PDL 细胞的作用极小。
8-O-acetylharpagide (1 mM; 24 h) 可显著增强人下咽癌 FaDu 细胞的放射敏感性,但对人正常 PDL 细胞的放射敏感性无影响。

Western Blot Analysis

Cell Line: old human dermal fibroblasts (HDFs)
Concentration: 0.5 μM, 1 μM, 5 μM, 10 μM
Incubation Time: 48 h
Result: Reduced p53 expression to ~90% of control at 0.5 μM.
Reduced p53 expression to ~75% of control at 1 μM.
Reduced p53 expression to ~60% of control at 5 μM.
Reduced p53 expression to ~55% of control at 10 μM, all in a dose-dependent manner.

Cell Cytotoxicity Assay

Cell Line: human hypopharyngeal cancer FaDu cells, human periodontal ligament (PDL) normal cells
Concentration: 0.01, 0.1, 0.3, 0.5, 0.7, 1 mM
Incubation Time: 24 h
Result: Reduced viability of FaDu cells significantly at concentrations ≥ 0.5 mM, with an IC50 of 0.88 mM.
Reached an IC50 of 1.65 mM in PDL cells, yielding a selectivity index of ≈1.85.
Enhanced PDL cell viability at low concentrations.

Cell Proliferation Assay

Cell Line: human hypopharyngeal cancer FaDu cells
Concentration: 1 mM
Incubation Time: 6 days
Result: Completely suppressed the proliferation of FaDu cells over the 6-day period, while vehicle-treated cells showed continuous growth.

Cell Cycle Analysis

Cell Line: human hypopharyngeal cancer FaDu cells, human periodontal ligament (PDL) normal cells
Concentration: 0.5, 1 mM
Incubation Time: 24 h
Result: Induced dramatic G2/M phase arrest and an increased sub-G1 population in FaDu cells treated with 1 mM, with a dose-dependent effect from 0.5-1 mM.
Upregulated CHK1 (1.32-fold), Cyclin B (1.3-fold), and p21 (1.74-fold), and downregulated CDK1 (0.58-fold) relative to GAPDH in FaDu cells.
Showed no significant changes in cell cycle distribution or cell cycle-related protein expression in PDL cells at the same concentrations.

Apoptosis Analysis

Cell Line: human hypopharyngeal cancer FaDu cells, human periodontal ligament (PDL) normal cells
Concentration: 1 mM
Incubation Time: 24 h
Result: Induced a significant increase in necrosis-like cell population and late apoptosis, with no significant change in early apoptosis in FaDu cells.
Downregulated AKT (0.56-fold), phospho-AKT (0.64-fold), and BCL-2 (0.7-fold) relative to GAPDH in FaDu cells.
Caused only a small increase in necrosis-like cells and no significant changes in apoptosis or apoptosis-related protein expression in PDL cells.

Cell Cytotoxicity Assay

Cell Line: human hypopharyngeal cancer FaDu cells, human periodontal ligament (PDL) normal cells
Concentration: 1 mM
Incubation Time: 24 h (pre-incubation); 48 h (post-irradiation incubation)
Result: Enhanced the radiosensitivity of FaDu cells significantly, with cell viability decreasing more sharply with increasing radiation dose compared to vehicle-treated FaDu cells.
Showed no enhancement of radiosensitivity in PDL cells.
体内研究
(In Vivo)

8-O-acetylharpagide (75-150 mg/kg;口服;每日 1 次;连续 4 周) 可显著抑制荷 4T1 乳腺癌 Balb-C 小鼠体内的 AKT/NF-κB/MMP9 信号轴。
8-O-acetylharpagide (低剂量;口服) 可抑制衰老小鼠的衰老表型。

Animal Model: Balb-C (female, 4 weeks old, weight 22 g, subcutaneous injection of 4T1 cells)
Dosage: 75 mg/kg; 150 mg/kg
Administration: p.o.; once daily; 4 weeks
Result: Significantly reduced relative protein levels of AKT, p-AKT, NF-κB p65, and MMP9 compared to the control group.
Significantly reduced the p-AKT/AKT ratio compared to the control group.
Further significantly reduced relative protein levels of AKT, p-AKT, NF-κB p65, and MMP9 compared to the control group.
性状 固体
颜色 White to off-white

化学信息

分子量 406.38
分子式 C17H26O11
CAS No. 6926-14-3
别名 8-O-乙酰哈巴苷

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.92 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (61.52 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4608 mL12.3038 mL24.6075 mL61.5188 mL
5 mM0.4922 mL2.4608 mL4.9215 mL12.3038 mL
10 mM0.2461 mL1.2304 mL2.4608 mL6.1519 mL
15 mM0.1641 mL0.8203 mL1.6405 mL4.1013 mL
20 mM0.1230 mL0.6152 mL1.2304 mL3.0759 mL
25 mM0.0984 mL0.4922 mL0.9843 mL2.4608 mL
30 mM0.0820 mL0.4101 mL0.8203 mL2.0506 mL
40 mM0.0615 mL0.3076 mL0.6152 mL1.5380 mL
50 mM0.0492 mL0.2461 mL0.4922 mL1.2304 mL
60 mM0.0410 mL0.2051 mL0.4101 mL1.0253 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础